Germany’s Merck KGaA (MKGAY), which had confirmed in February it was in advanced talks to buy SpringWorks Therapeutics (SWTX), is nearing a roughly $3.5B deal for the U.S. biopharmaceutical company that specializes in rare diseases and cancer, people familiar with the matter told The Wall Street Journal’s Ben Dummett and Lauren Thomas. The two parties have agreed on a price close to $47 per share, and a deal could be completed as soon as Monday, the report added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks EU approval would enhance strategic value, says Evercore
- Positive opinion for Ogsiveo would de-risk SpringWorks deal, says Barclays
- SpringWorks Therapeutics price target lowered to $84 from $87 at BofA
- Merck KGaA says ‘no certainty’ SpringWorks deal will be signed
- SpringWorks cancelled from conference this week, says Barclays
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue